RMD Resmed Inc

  1. Stocks
  2. Healthcare
  3. NYSE: RMD

Price (delayed)

$214.28

Market cap

$31.05B

P/E Ratio

45.59

Dividend/share

$1.56

EPS

$4.7

Enterprise value

$31.82B

Sector: Healthcare
Industry: Medical Instruments & Supplies
Website: https://www.resmed.com/

ResMed is a San Diego, California-based medical equipment company. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea , chronic obstructive pulmonary disease , and other respiratory ...

Highlights

RMD's net income has soared by 62% YoY and by 9% QoQ
The EPS has soared by 60% YoY and by 9% from the previous quarter
Resmed's quick ratio has increased by 24% YoY but it has decreased by 3.8% from the previous quarter
The price to earnings (P/E) is 22% higher than the 5-year quarterly average of 37.3 and 7% higher than the last 4 quarters average of 42.8

Key stats

What are the main financial stats of RMD
Market
Shares outstanding
144.92M
Market cap
$31.05B
Enterprise value
$31.82B
Valuations
Price to earnings (P/E)
45.59
Price to book (P/B)
11.59
Price to sales (P/S)
10.25
EV/EBIT
38.13
EV/EBITDA
31.14
EV/Sales
10.51
Earnings
Revenue
$3.03B
EBIT
$834.58M
EBITDA
$1.02B
Free cash flow
$697.73M
Per share
EPS
$4.7
Free cash flow per share
$4.82
Book value per share
$18.49
Revenue per share
$20.9
TBVPS
$15.79
Balance sheet
Total assets
$4.62B
Total liabilities
$1.94B
Debt
$1.19B
Equity
$2.68B
Working capital
$951.76M
Liquidity
Debt to equity
0.44
Current ratio
2.61
Quick ratio
1.5
Net debt/EBITDA
0.75
Margins
EBITDA margin
33.8%
Gross margin
58.3%
Net margin
22.5%
Operating margin
28.3%
Efficiency
Return on assets
15%
Return on equity
28.1%
Return on invested capital
32.1%
Return on capital employed
20.7%
Return on sales
27.6%
Dividend
Dividend yield
0.73%
DPS
$1.56
Payout ratio
33.2%

RMD stock price

How has the Resmed stock price performed over time
Intraday
-3.6%
1 week
-1.69%
1 month
0.88%
1 year
33.41%
YTD
0.81%
QTD
0.81%

Financial performance

How have Resmed's revenue and profit performed over time
Revenue
$3.03B
Gross profit
$1.76B
Operating income
$855.45M
Net income
$679.9M
Gross margin
58.3%
Net margin
22.5%
RMD's net income has soared by 62% YoY and by 9% QoQ
Resmed's net margin has increased by 45% YoY and by 7% QoQ
RMD's operating income is up by 41% YoY and by 6% QoQ
RMD's operating margin is up by 26% year-on-year and by 3.3% since the previous quarter

Growth

What is Resmed's growth rate over time

Valuation

What is Resmed stock price valuation
P/E
45.59
P/B
11.59
P/S
10.25
EV/EBIT
38.13
EV/EBITDA
31.14
EV/Sales
10.51
The EPS has soared by 60% YoY and by 9% from the previous quarter
The price to earnings (P/E) is 22% higher than the 5-year quarterly average of 37.3 and 7% higher than the last 4 quarters average of 42.8
RMD's P/B is 59% above its 5-year quarterly average of 7.3 and 17% above its last 4 quarters average of 9.9
RMD's equity is up by 27% year-on-year and by 7% since the previous quarter
The P/S is 65% higher than the 5-year quarterly average of 6.2 and 25% higher than the last 4 quarters average of 8.2
The company's revenue rose by 12% YoY and by 2.4% QoQ

Efficiency

How efficient is Resmed business performance
The ROA has increased by 46% YoY and by 6% from the previous quarter
Resmed's ROE has increased by 37% YoY and by 3.3% from the previous quarter
The company's return on invested capital rose by 30% YoY and by 7% QoQ
The ROS has increased by 30% YoY and by 5% from the previous quarter

Dividends

What is RMD's dividend history
DPS
$1.56
Dividend yield
0.73%
Payout ratio
33.2%
Recent dividends

Financial health

How did Resmed financials performed over time
The company's total assets is 138% higher than its total liabilities
Resmed's quick ratio has increased by 24% YoY but it has decreased by 3.8% from the previous quarter
The current ratio has grown by 24% YoY and by 3.2% from the previous quarter
Resmed's debt is 56% lower than its equity
Resmed's debt to equity has decreased by 29% YoY and by 15% QoQ
RMD's equity is up by 27% year-on-year and by 7% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.